| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PD 153035 | CTRPv2 | pan-cancer | AAC | 0.03 | 0.6 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | -0.022 | 0.6 |
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | -0.085 | 0.6 |
| mRNA | AZD-2281 | CTRPv2 | pan-cancer | AAC | -0.023 | 0.6 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.024 | 0.6 |
| mRNA | GSK1070916 | GDSC1000 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | lenalidomide | FIMM | pan-cancer | AAC | 0.094 | 0.6 |
| mRNA | VU0155056 | CTRPv2 | pan-cancer | AAC | 0.024 | 0.6 |
| mRNA | XMD8-85 | GDSC1000 | pan-cancer | AAC | -0.035 | 0.6 |
| mRNA | SB 216763 | GDSC1000 | pan-cancer | AAC | 0.026 | 0.6 |